Chimeric anti-CD14 IGG2/4 hybrid antibodies for therapeutic intervention in pig and human models of inflammation

Journal of Immunology

Volumn 191, Issue 9, 2013, Pages 4769-4777

  Lau, Corinna ^a   Gunnarsen, Kristin S ^b,c   Høydahl, Lene S ^b,c   Andersen, Jan Terje ^b,c   Berntzen, Gøril ^b,c   Pharo, Anne ^c   Lindstad, Julie K ^c   Ludviksen, Judith K ^a   Brekke, Ole Lars ^a,d   Barratt Due, Andreas ^c   Nielsen, Erik Waage ^a,d   Stokes, Christopher R ^e   Espevik, Terje ^f   Sandlie, Inger ^b,c   Mollnes, Tom Eirik ^a,c,d,f  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIBODY MIL2; CD14 ANTIGEN; CD14 IMMUNOGLOBULIN G2 IMMUNOGLOBULIN G4 ANTIBODY 18D11; CHIMERIC ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5 INHIBITOR OMCI; ECULIZUMAB; FC RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; NEONATAL FC RECEPTOR; RECOMBINANT ANTIBODY; RECOMBINANT CD14 ANTIBODY MIL2; RECOMBINANT CD14 IMMUNOGLOBULIN G2 IMMUNOGLOBULIN G4 ANTIBODY 18D11; RITUXIMAB; THROMBOPLASTIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIBODY; ANTIIDIOTYPIC ANTIBODY; DIFFERENTIATION ANTIGEN; FCGR1A PROTEIN, HUMAN; IMMUNOGLOBULIN G; LEU-13 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; COMBINATION CHEMOTHERAPY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; MOLECULAR CLONING; MOLECULAR INTERACTION; MONOTHERAPY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; ANIMAL; CELL LINE; HEK293 CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY;

ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION; CELL LINE; COMPLEMENT ACTIVATION; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INFLAMMATION; RECEPTORS, IGG; SUS SCROFA;

EID: 84885993158     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301653     Document Type: Article

References (58)

1. Wright, S. D., R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249: 1431-1433.
2. Ulevitch, R. J., and P. S. Tobias. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13: 437-457.
3. Jersmann, H. P. 2005. Time to abandon dogma: CD14 is expressed by nonmyeloid lineage cells. Immunol. Cell Biol. 83: 462-467.
4. Weber, C., C. Müller, A. Podszuweit, C. Montino, J. Vollmer, and A. Forsbach. 2012. Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology 136: 64-77.
5. Pugin, J., I. D. Heumann, A. Tomasz, V. V. Kravchenko, Y. Akamatsu, M. Nishijima, M. P. Glauser, P. S. Tobias, and R. J. Ulevitch. 1994. CD14 is a pattern recognition receptor. Immunity 1: 509-516.
6. Osterbye, T., D. P. Funda, P. Fundová, J. E. Månsson, H. Tlaskalová-Hogenová, and K. Buschard. 2010. A subset of human pancreatic beta cells express functional CD14 receptors: a signaling pathway for beta cell-related glycolipids, sulfatide and β-galactosylceramide. Diabetes Metab. Res. Rev. 26: 656-667.
7. Miller, Y. I., S. H. Choi, P. Wiesner, L. Fang, R. Harkewicz, K. Hartvigsen, A. Boullier, A. Gonen, C. J. Diehl, X. Que, et al. 2011. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108: 235-248.
8. Shirey, K. A., W. Lai, A. J. Scott, M. Lipsky, P. Mistry, L. M. Pletneva, C. L. Karp, J. McAlees, T. L. Gioannini, J. Weiss, et al. 2013. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497: 498-502.
9. Brekke, O. H., and I. Sandlie. 2003. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2: 52-62.
10. Beck, A., T. Wurch, C. Bailly, and N. Corvaia. 2010. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10: 345-352.
11. Chan, A. C., and P. J. Carter. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10: 301-316.
12. Roopenian, D. C., and S. Akilesh. 2007. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7: 715-725.
13. Nimmerjahn, F., and J. V. Ravetch. 2010. Antibody-mediated modulation of immune responses. Immunol. Rev. 236: 265-275.
14. Mueller, J. P., M. A. Giannoni, S. L. Hartman, E. A. Elliott, S. P. Squinto, L. A. Matis, and M. J. Evans. 1997. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol. Immunol. 34: 441-452.
15. Rother, R. P., S. A. Rollins, C. F. Mojcik, R. A. Brodsky, and L. Bell. 2007. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25: 1256-1264.
16. Leturcq, D. J., A. M. Moriarty, G. Talbott, R. K. Winn, T. R. Martin, and R. J. Ulevitch. 1996. Antibodies against CD14 protect primates from endotoxininduced shock. J. Clin. Invest. 98: 1533-1538.
17. Thorgersen, E. B., B. C. Hellerud, E. W. Nielsen, A. Barratt-Due, H. Fure, J. K. Lindstad, A. Pharo, E. Fosse, T. I. Tønnessen, H. T. Johansen, et al. 2010. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 24: 712-722.
18. Axtelle, T., and J. Pribble. 2003. An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody. J. Endotoxin Res. 9: 385-389.
19. Reinhart, K., T. Glück, J. Ligtenberg, K. Tschaikowsky, A. Bruining, J. Bakker, S. Opal, L. L. Moldawer, T. Axtelle, T. Turner, et al. 2004. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit. Care Med. 32: 1100-1108.
20. Khodoun, M. V., R. Strait, L. Armstrong, N. Yanase, and F. D. Finkelman. 2011. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc. Natl. Acad. Sci. USA 108: 12413-12418.
21. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
22. Brekke, O. L., D. Christiansen, H. Fure, M. Fung, and T. E. Mollnes. 2007. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J. Leukoc. Biol. 81: 1404-1413.
23. Brekke, O. L., D. Christiansen, H. Fure, A. Pharo, M. Fung, J. Riesenfeld, and T. E. Mollnes. 2008. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol. Immunol. 45: 3804-3813.
24. Hellerud, B. C., J. Stenvik, T. Espevik, J. D. Lambris, T. E. Mollnes, and P. Brandtzaeg. 2008. Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation. Infect. Immun. 76: 4183-4189.
25. Thorgersen, E. B., A. Pharo, K. Haverson, A. K. Axelsen, P. Gaustad, G. J. Kotwal, G. Sfyroera, and T. E. Mollnes. 2009. Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect. Immun. 77: 725-732.
26. Salvesen, B., J. Stenvik, C. Rossetti, O. D. Saugstad, T. Espevik, and T. E. Mollnes. 2010. Meconium-induced release of cytokines is mediated by the TRL4/MD-2 complex in a CD14-dependent manner. Mol. Immunol. 47: 1226-1234.
27. Brekke, O. L., C. Waage, D. Christiansen, H. Fure, H. Qu, J. D. Lambris, B. Osterud, E. W. Nielsen, and T. E. Mollnes. 2013. The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood. Adv. Exp. Med. Biol. 734: 123-136.
28. Meurens, F., A. Summerfield, H. Nauwynck, L. Saif, and V. Gerdts. 2012. The pig: a model for human infectious diseases. Trends Microbiol. 20: 50-57.
29. Nunn, M. A., A. Sharma, G. C. Paesen, S. Adamson, O. Lissina, A. C. Willis, and P. A. Nuttall. 2005. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J. Immunol. 174: 2084-2091.
30. Barratt-Due, A., E. B. Thorgersen, J. K. Lindstad, A. Pharo, O. Lissina, J. D. Lambris, M. A. Nunn, and T. E. Mollnes. 2011. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J. Immunol. 187: 4913-4919.
31. Norderhaug, L., T. Olafsen, T. E. Michaelsen, and I. Sandlie. 1997. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J. Immunol. Methods 204: 77-87.
32. Sanz, G., E. Pérez, A. Jiménez-Marín, F. Mompart, L. Morera, M. Barbancho, D. Llanes, and J. J. Garrido. 2007. Molecular cloning, chromosomal location, and expression analysis of porcine CD14. Dev. Comp. Immunol. 31: 738-747.
33. Summerfield, A., and K. C. McCullough. 1997. Porcine bone marrow myeloid cells: phenotype and adhesion molecule expression. J. Leukoc. Biol. 62: 176-185.
34. Berntzen, G., E. Lunde, M. Flobakk, J. T. Andersen, V. Lauvrak, and I. Sandlie. 2005. Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J. Immunol. Methods 298: 93-104.
35. Andersen, J. T., S. Foss, V. E. Kenanova, T. Olafsen, I. S. Leikfoss, D. C. Roopenian, A. M. Wu, and I. Sandlie. 2012. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J. Biol. Chem. 287: 22927-22937.
36. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegård, J. Köhl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
37. Barratt-Due, A., E. B. Thorgersen, K. Egge, S. E. Pischke, A. Sokolov, B. C. Hellerud, J. K. Lindstad, A. Pharo, A. K. Bongoni, R. Rieben, et al. 2013. Combined inhibition of complement (C5) and CD14 markedly attenuates inflammation, thrombogenicity and hemodynamic changes in porcine sepsis. J. Immunol. 191: 819-827.
38. Lappegård, K. T., D. Christiansen, A. Pharo, E. B. Thorgersen, B. C. Hellerud, J. Lindstad, E. W. Nielsen, G. Bergseth, D. Fadnes, T. G. Abrahamsen, et al. 2009. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. USA 106: 15861-15866.
39. Barratt-Due, A., E. B. Thorgersen, J. K. Lindstad, A. Pharo, O. L. Brekke, D. Christiansen, J. D. Lambris, and T. E. Mollnes. 2010. Selective inhibition of TNF-alpha or IL-1 beta does not affect E. coli-induced inflammation in human whole blood. Mol. Immunol. 47: 1774-1782.
40. Hamilton, R. G. 1987. Human IgG subclass measurements in the clinical laboratory. Clin. Chem. 33: 1707-1725.
41. Schroeder, H. W., Jr., and L. Cavacini. 2010. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125(2, Suppl 2)S41-S52.
42. Sondermann, P., J. Kaiser, and U. Jacob. 2001. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol. 309: 737-749.
43. Ramsland, P. A., W. Farrugia, T. M. Bradford, C. T. Sardjono, S. Esparon, H. M. Trist, M. S. Powell, P. S. Tan, A. C. Cendron, B. D. Wines, et al 2011. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 187: 3208-3217.
44. Halloran, P. J., S. E. Sweeney, C. M. Strohmeier, and Y. B. Kim. 1994. Molecular cloning and identification of the porcine cytolytic trigger molecule G7 as a Fc gamma RIII alpha (CD16) homologue. J. Immunol. 153: 2631-2641.
45. Qiao, S., G. Zhang, C. Xia, H. Zhang, Y. Zhang, J. Xi, H. Song, and X. Li. 2006. Cloning and characterization of porcine Fc gamma receptor II (FcgammaRII). Vet. Immunol. Immunopathol. 114: 178-184.
46. Zhang, G., S. Qiao, Q. Li, X. Wang, Y. Duan, L. Wang, Z. Xiao, and C. Xia. 2006. Molecular cloning and expression of the porcine high-affinity immunoglobulin G Fc receptor (FcgammaRI). Immunogenetics 58: 845-849.
47. Stirling, C. M., B. Charleston, H. Takamatsu, S. Claypool, W. Lencer, R. S. Blumberg, and T. E. Wileman. 2005. Characterization of the porcine neonatal Fc receptor - potential use for trans-epithelial protein delivery. Immunology 114: 542-553.
48. Vaughn, D. E., and P. J. Bjorkman. 1998. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 6: 63-73.
49. Kim, J. I., C. J. Lee, M. S. Jin, C. H. Lee, S. G. Paik, H. Lee, and J. O. Lee. 2005. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J. Biol. Chem. 280: 11347-11351.
50. Albright, S., B. Chen, K. Holbrook, and N. U. Jain. 2008. Solution NMR studies provide structural basis for endotoxin pattern recognition by the innate immune receptor CD14. Biochem. Biophys. Res. Commun. 368: 231-237.
51. Kelley, S. L., T. Lukk, S. K. Nair, and R. I. Tapping. 2013. The crystal structure of human soluble CD14 reveals a bent solenoid with a hydrophobic aminoterminal pocket. J. Immunol. 190: 1304-1311.
52. Köhl, J. 2006. Self, non-self, and danger: a complementary view. Adv. Exp. Med. Biol. 586: 71-94.
53. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
54. Hawlisch, H., and J. Köhl. 2006. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol. Immunol. 43: 13-21.
55. Hajishengallis, G., and J. D. Lambris. 2010. Crosstalk pathways between Tolllike receptors and the complement system. Trends Immunol. 31: 154-163.
56. Song, W. C. 2012. Crosstalk between complement and toll-like receptors. Toxicol. Pathol. 40: 174-182.
57. Mollnes, T. E., D. Christiansen, O. L. Brekke, and T. Espevik. 2008. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv. Exp. Med. Biol. 632: 253-263.
58. Barratt-Due, A., S. E. Pischke, O. L. Brekke, E. B. Thorgersen, E. W. Nielsen, T. Espevik, M. Huber-Lang, and T. E. Mollnes. 2012. Bride and groom in systemic inflammation - the bells ring for complement and Toll in cooperation. Immunobiology 217: 1047-1056.